Sensyne to Collaborate with Bristol Myers Squibb on Blood-Disease Research
October 23 2020 - 4:12AM
Dow Jones News
By Joe Hoppe
Sensyne Health PLC said Friday that it has signed a research
collaboration agreement for an undisclosed amount with Bristol
Myers Squibb, applying its technology to conduct research into rare
blood diseases.
The U.K. clinical-technology company said the collaboration will
initially focus on applying its machine-learning technology to
research disease progression and patient stratification for
patients within the Myeloproliferative Neoplasms group of rare
blood diseases. Patients within this group have diseases
characterized by the overproduction of one or more types of blood
cells.
Sensyne said the collaboration will be its fourth successive
partnership with a major pharmaceutical company, following
collaborations signed with Bayer AG, Roche Holding AG and Alexion
Pharmaceuticals Inc.
"As we continue to see wider adoption of clinical artifical
intelligence and machine learning by the life sciences industry to
support pharmaceutical research, Sensyne is ideally positioned to
help accelerate the discovery and development of new medicines for
patients," said Chief Executive Paul Drayson.
Shares at 0739 GMT were up 7 pence, or 8%, at 99.5 pence.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
October 23, 2020 03:57 ET (07:57 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024